Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 3/20 | 0.55 |
| ▸ | GABRD | O14764 | 3/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.55 |
| ▸ | GABRE | P78334 | 3/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6973438 | 0.85 | HSD17B10 (0.66) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL11346077 | 0.84 | ATM (0.57) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL4098385 | 0.82 | AURKA (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL29367625 | 0.81 | LMNA (0.65) | ALDH1A1MAPTHPGDLMNAGABRP | |
| SCHEMBL699273 | 0.81 | LMNA (0.65) | ALDH1A1MAPTHPGDLMNAGABRP | |
| SCHEMBL30615640 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL28904576 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL4931135 | 0.80 | GABRP (0.56) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL28492436 | 0.80 | SMN1; SMN2 (0.57) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL11356816 | 0.80 | ATM (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-1120420-B1 | Triphendioxazine compounds | CLARIANT FINANCE BVI LTD (VG) | 2006-01-11 | — | — | EP | disclosed |
| US-6617453-B1 | Preparing these triphendioxazine compounds by a cyclization step conducted in the presence of manganese dioxide and concentrated sulphuric acid. | CLARIANT FINANCE (BVI) LIMITED (VG) | 2003-09-09 | — | — | US | disclosed |
| EP-0911337-B1 | Process for the preparation of triphendioxazine compounds | CLARIANT FINANCE BVI LTD (VG) | 2003-02-26 | — | — | EP | disclosed |
| US-6355795-B1 | PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER AND ARE ALSO EASILY DISPERSIBLE | CLARIANT FINANCE (BVI) LIMITED (BV) | 2002-03-12 | — | — | US | disclosed |
| EP-1120421-A2 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 2001-08-01 | — | — | EP | disclosed |
| EP-1120420-A2 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 2001-08-01 | — | — | EP | disclosed |
| US-6255482-B1 | PREPARING CHLORINE-CONTAINING TRIPHENDIOXAZINE COMPOUNDS USEFUL AS PIGMENTS POSSESSING HIGH FASTNESS TO SOLVENTS, MIGRATION, AND LIGHT, WHICH HAVE GOOD THERMAL STABILITIES AND HIGH TINTING POWER | CLARIANT FINANCE (BVI) LIMITED (VG) | 2001-07-03 | — | — | US | disclosed |
| EP-0911337-A1 | New triphendioxazine compounds | Clariant Finance (BVI) Limited (VG) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | ALDH1A1 4726/4885MAPT 1623/4885HPGD 943/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | ALDH1A1 4726/4885MAPT 1623/4885HPGD 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.